Huadong Medicine Co., Ltd (SHE: 000963), a prominent pharmaceutical company in China, has entered into an exclusive licensing agreement with Suzhou Auzone Biological Technology Co., Ltd, focusing on Auzone’s product candidate TTYP01, an oral formulation of edaravone. This strategic partnership positions Huadong to exclusively develop, regulate, manufacture, and commercialize the drug across mainland China, Hong Kong, Macau, and Taiwan.
Under the terms of the agreement, Huadong will make an upfront payment of RMB 100 million (USD 13.8 million) to Auzone and is further committed to milestone payments of up to RMB 1.185 billion (USD 163.2 million) tied to development, regulatory, and sales achievements. Additionally, Auzone is eligible to receive double-digit tiered royalties based on the net sales of the drug.
Edaravone, a hydroxyl radical scavenger originally developed by Mitsubishi Tanabe Pharma Corporation, was first approved in Japan in June 2015, with subsequent approvals in the U.S. in May 2017 and China in August 2019. While the originator drug and most generics are administered via infusion or injection, TTYP01 represents an innovative oral tablet formulation. This modified version has completed Phase III clinical trials in China for the treatment of acute ischemic stroke and is currently under investigation for its potential use in pediatric autism spectrum disorder (ASD), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and acute altitude sickness.- Flcube.com
